This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Campus
  1. Article
  2. Source: Campus Sanofi
  3. 22 Oct 2023

SPARTA study

Author: Sanofi

Editorial Team

    

Prescribing Information Toujeo (insulin glargine 300 units/mL)

toujeo logo
Sanofi is here to support you and your patients.

Ask us your questions about our products, patient materials or organising a meeting.

SPARTA summary

Sparta Summary

In this clinical summary you discover the real-world evidence of Toujeo in people with T1 diabetes living in UK. This was conducted in the SPARTA study - a descriptive, retrospective study.

Sparta Video

In the short video (2.35 min) you’ll learn about the results of the SPARTA study in T1 diabetes. This descriptive, retrospective study represents the real-world experience of using Toujeo® in 300 patients with T1DM in the UK.

SEE MORE FROM SCIENCE

Toujeo

Toujeo® is indicated as treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years. 

Patient Website

Find resources and support for your patients on Toujeo®. Help patients understand the basics of living and staying well with diabetes and how to have a positive start and experience with the medication prescribed to them.

MAT-XU-2205632 (v5.0) Date of Preparation: October 2023